Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DA-1301
- Development stage
- Preclinical
- Lead developer
- Cingulate
- Modality
- Cell Therapies, Gene Therapies
01
Overview
DA-1301 is an investigational cell and gene therapy (CGT) candidate being developed by the South Korean pharmaceutical company Dong-A ST. Currently in the preclinical stage, the therapy is being explored for its potential in treating inflammatory and neurodegenerative diseases. As a next-generation therapeutic asset, DA-1301 represents the company's strategic shift toward advanced modalities, although specific details regarding its molecular target, cellular source, or genetic payload have not yet been publicly disclosed. The program aims to leverage the regenerative or immunomodulatory properties of cell-based interventions to address chronic conditions with high unmet medical needs.
Beyond the preview
Go deeper on DA-1301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DA-1301.